FDA Approves New Strengths of Acne Drug Solodyn

Medicis Pharmaceutical Corp. Aug. 30 announced that the Food and Drug Administration has approved Solodyn (minocycline) extended release tablets in 55 milligrams (mg), 80 mg, and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

Solodyn extended release tablets now are approved in the 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, and 135 mg dosages, the Scottsdale, Ariz.-based company said.

Medicis said it believes all forms of Solodyn currently approved for use, including the 55 mg, 80 mg, ...